Company Overview and News
February was a crazy month for investors; consequently, the landscape of best-performing exchange-traded funds expanded from primarily biotech and emerging-market ETFs in January to several other spaces for this edition of the best ETFs of the month.
The logic for Petroleo Brasileiro SA Petrobras's (NYSE:PBR.A) Buy recommendation, which was recently up graded from a Hold to is based in part on a mathematical computation of risk/reward that is much better than average, analytical scoring that is below average, and a ranking in the company's sector group that is in the top quarter, and a ranking in its industry group that is in the top third. The Buy recommendation for PBR.
When compiling a list of the best ETFs of the month, the first twenty or so will undoubtedly be double- or triple-leveraged funds. But what happens when you exclude these funds from the list and focus solely on more standard exchange-traded funds? After all, these leveraged funds involve significantly higher risk and their default nature gives them an upper hand in performance … in a way, they’re “cheaters.
Portfolio Grader currently ranks Petroleo Brasileiro SA Petrobras (NYSE:PBR) a Hold. The methods for fundamental and quantitative metrics used in this analytical tool evaluates and ranks nearly 5,000 stocks each week. This represents no change from the previous week and is the same ranking PBR has had from Portfolio Grader for 2 months. The Hold recommendation for Petroleo Brasileiro SA Petrobras resulted from a process of analysis that is proprietary which yielded outcomes that were above average in 3 areas: an industry group ranked above average in attractiveness, a ranking in the company's sector that is in the top half, and a mathematical computation of risk/reward that is better than average; and produced below average conclusions in 3 areas: an economic sector rated below average in attractiveness, ranking in its industry group that is in the middle third-below average, and analytical scores that are below average.
Currently, Petroleo Brasileiro SA Petrobras (NYSE:PBR) has a Hold using the Portfolio Grader analytical stock evaluator. The system for fundamental and quantitative metrics used in this analytical tool researches and ranks nearly 5,000 stocks each week. The current Portfolio Grader recommendation on the shares has been in place for 2 months. Petroleo Brasileiro SA Petrobras's Hold recommendation is the outcome of a proprietary process of evaluation and produced results that were above average in 3 areas: an industry group rated above average in attractiveness, a ranking in its sector group that is in the top half, and a numerical calculation of risk/reward that is better than average; and produced below average outcomes in 3 areas: an economic sector rated below average in attractiveness, ranking in the company's industry group that is in the middle third-below average, and analytical scoring that is below average.
Petroleo Brasileiro SA Petrobras (NYSE:PBR.A) is a member of the 20 company Integrated Oil GICS industry group, which is part of the 186 company GICS Energy Minerals sector. The market value of PBR.A is $32.1 billion which places it in the lower half of its industry group. The current Portfolio Grader ranking for PBR.A puts it 11 among the 20 companies in this industry group, giving it a below-average spot; in the top half of the sector with a ranking of 65 among the 186 companies in the sector, and number 2,144 in the nearly 5,000 company Portfolio Grader universe.
As one of the 186 companies in the GICS Energy Minerals sector Petroleo Brasileiro SA Petrobras (NYSE:PBR) is a component of the 20 company Integrated Oil GICS industry group within this sector. PBR has a market value of $45.3 billion which is in the bottom half of its industry group. The current Portfolio Grader ranking for PBR puts it 14 among the 20 companies in this industry group, giving it a lower than average position; in the top half of the sector with a ranking of 86 among the 186 companies in the sector, and number 2,576 in the nearly 5,000 company Portfolio Grader universe.
With a $42.7 billion market value, Petroleo Brasileiro SA Petrobras (NYSE:PBR) ranks in the lower half of its industry group, Integrated Oil, and in the top decile of sector group, Energy Minerals, in market value. From the vantage point of investment attractiveness, the stock's Portfolio Grader ranking currently places it 15 among the 20 companies in this industry group, a spot that is well below-average; in the third quartile of the sector with a ranking of 120 among the 186 companies in the sector, and number 3,138 in the nearly 5,000 company Portfolio Grader universe.
Currently, Petroleo Brasileiro SA Petrobras (NYSE:PBR) has a Sell using the approach to investing of Louis Navellier and his Portfolio Grader stock evaluator. PBR has been downgraded from a Hold to a Sell in the last week.
Petroleo Brasileiro SA Petrobras (NYSE:PBR) is ranked as a Sell using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing system. PBR has been downgraded from a Hold to a Sell in the last week.
Petroleo Brasileiro SA Petrobras (NYSE:PBR) is classified as a member of the 20 company Integrated Oil GICS industry group, which is a segment of the 185 company GICS Energy Minerals sector. PBR's market value is $41.2 billion which falls in the lower half of its industry group. The stock's Portfolio Grader ranking currently places it 15 among the 20 companies in this industry group, a position that is well below-average; in the top half of the sector with a ranking of 90 among the 185 companies in the sector, and number 2,698 in the nearly 5,000 company Portfolio Grader universe.
BP plc (ADR) (NYSE:BP) has had a nice rally of late. Buoyed by rising Brent crude prices, the BP stock price has risen 20% just since mid-August, reaching a two-year high in the process.
* Petroleo Brasileiro Sa Petrobras - Announced pricing of 2 series of global notes denominated in US dollars to be issued by unit Petrobras Global Finance Source text for Eikon: Further company coverage:
The energy sector has been on a volatile roller-coaster ride for the past few months. Oil prices rebounded when the Organization of Petroleum Exporting Countries (OPEC) announced last November that it was going to cap oil-production, then collapsed when the Energy Information Administration (EIA) announced larger-than-expected crude-oil inventory builds.
Unwilling or unable to follow through on yesterday’s move to record highs, the bulls were suspiciously absent from Tuesday’s action … despite a lack of a clear bearish catalyst. By the time the closing bell rang, the S&P 500 was at 2,437.03, down 0.67%.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET